Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Non-Muscle Invasive Bladder Cancer Global Market Report 2025
Download Free Sample Buy Now
Global Non Muscle Invasive Bladder Cancer Market Report 2025

Report Price : $4490.00

Pages :

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Non-Muscle Invasive Bladder Cancer Global Market Report 2025

By Stage (Carcinoma In Situ (CIS), T1 Stage, Ta Stage), By Treatment (Immunotherapy, Chemotherapy, Surgery, Intravesical Therapy, Others Treatments), By Tumor (Low-Grade Tumours, High-Grade Tumours), By End-User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Non-Muscle Invasive Bladder Cancer Market Overview

• Non-Muscle Invasive Bladder Cancer market size has reached to $3.46 billion in 2024

• Expected to grow to $4.58 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%

• Growth Driver: The Growing Demand for Minimally Invasive Procedures Driving The Market

• Market Trend: Advancing Immunotherapy With FDA Approval Of ANKTIVA For BCG-Unresponsive Bladder Cancer

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Non-Muscle Invasive Bladder Cancer Market?

Non-muscle invasive bladder cancer (NMIBC) refers to a type of bladder cancer that is confined to the inner layers of the bladder wall and has not spread to the muscle layer. It is typically diagnosed at an early stage and can often be treated effectively with methods such as transurethral resection, intravesical therapy, or close surveillance.

The main stages in the non-muscle invasive bladder cancer market are carcinoma in situ (CIS), T1 stage, and Ta stage. Carcinoma in situ is a form of non-muscle-invasive bladder cancer where abnormal cells are found in the bladder lining but have not spread into deeper tissues. The various treatments include Immunotherapy, chemotherapy, surgery, intravesical therapy, and others, and several tumors, including low-grade tumors and high-grade tumors. The different end users encompass hospital pharmacies, retail pharmacies, and online pharmacies.

Non-Muscle Invasive Bladder Cancer Market Size and growth rate 2025 to 2029: Graph

What Is The Non-Muscle Invasive Bladder Cancer Market Size 2025 And Growth Rate?

The non-muscle invasive bladder cancer market size has grown strongly in recent years. It will grow from $3.46 billion in 2024 to $3.66 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to growth in the aging population, growth in healthcare spending, growth in healthcare infrastructure, growth in telemedicine, and a rise in smoking rates.

What Is The Non-Muscle Invasive Bladder Cancer Market Growth Forecast?

The non-muscle invasive bladder cancer market size is expected to see strong growth in the next few years. It will grow to $4.58 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to rising adoption of targeted therapies, increasing focus on personalized medicine, growing investments in oncology research, growing demand for minimally invasive procedures, and rising incidence of chronic bladder. Major trends in the forecast period include technological advancements, precision medicine, artificial intelligence, telemedicine, and digital health tools.

The forecast of 5.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. medical supply chains by increasing costs for Bacillus Calmette-Guérin immunotherapy and blue light cystoscopy equipment imported from Canada and Germany, potentially leading to higher oncology surgery costs and delayed tumor surveillance. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Non-Muscle Invasive Bladder Cancer Market Segmented?

1) By Stage: Carcinoma In Situ (CIS), T1 Stage, Ta Stage

2) By Treatment: Immunotherapy, Chemotherapy, Surgery, Intravesical Therapy, Others Treatments

3) By Tumor: Low-Grade Tumours, High-Grade Tumours

4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Carcinoma In Situ (CIS): High-Grade CIS, Low-Grade CIS

2) By T1 Stage: T1a Stage (Superficial Tumors), T1b Stage (Invasive Into Lamina Propria)

3) By Ta Stage: Low-Grade Ta Stage, High-Grade Ta Stage

What Is Driving The Non-Muscle Invasive Bladder Cancer Market? The Growing Demand for Minimally Invasive Procedures Driving The Market

The growing demand for minimally invasive procedures is expected to propel the growth of the non-muscle invasive bladder cancer market going forward. Minimally invasive procedures are surgical techniques that utilize small incisions and specialized instruments to perform operations with less tissue damage, resulting in reduced pain, shorter recovery times, and minimal scarring compared to traditional open surgery. The increasing focus on minimally invasive procedures is driven by factors such as reduced recovery time, improved patient outcomes, and the growing aging population, which collectively enhance patient safety, satisfaction, and efficiency in healthcare. Non-muscle invasive bladder cancer enables minimally invasive procedures by allowing for localized treatments such as transurethral resection and intravesical therapy, which target the tumor without the need for extensive surgical intervention. For instance, in August 2023, according to The Aesthetic Society, a US-based organization of plastic surgery and cosmetic medicine, Americans spent more than $11.8 billion on aesthetic procedures overall, up 2% from the previous year. Therefore, the growing demand for minimally invasive procedures is driving the growth of the non-muscle invasive bladder cancer industry.

What Is Driving The Non-Muscle Invasive Bladder Cancer Market? Impact Of Personalized Medicine On Patient Outcomes In Cancer Care

The growing focus on personalized medicine is expected to propel the growth of the non-muscle invasive bladder cancer market going forward. Personalized medicine involves customizing medical treatment based on an individual's genetic profile, lifestyle, and environment for more effective outcomes. The growing focus on personalized medicine is driven by several factors, such as advancements in genomic research, improved diagnostic tools, and the growing demand for more targeted and effective treatments. Non-muscle invasive bladder cancer supports personalized medicine by enabling tailored treatment plans based on specific tumor characteristics, genetic markers, and individual patient profiles. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, this is driving the growth of the non-muscle invasive bladder cancer industry.

Who Are The Major Players In The Global Non-Muscle Invasive Bladder Cancer Market?

Major companies operating in the non-muscle invasive bladder cancer market are Johnson & Johnson, Janssen Research & Development LLC, Merck & Co. Inc., AstraZeneca plc, Moderna Inc., Astellas Pharma US Inc., Ferring Pharmaceuticals, EMD Serono Inc., Fidia Farmaceutici SpA, Genentech Inc., Aura Biosciences Inc., UroGen Pharma Ltd., Asieris Pharmaceuticals, Protara Therapeutics Inc., Hamlet Pharma AB, Istari Oncology Inc., Heat Biologics Inc., Telormedix SA, Viventia Bio Inc., Theralase Technologies Inc., Vaxiion Therapeutics Inc., ImmunityBio Inc., Altor BioScience Corporation, SURGE Therapeutics Inc.

What Are The Key Trends Of The Global Non-Muscle Invasive Bladder Cancer Market? Advancing Immunotherapy With FDA Approval Of ANKTIVA For BCG-Unresponsive Bladder Cancer

Major companies operating in the non-muscle invasive bladder cancer market are focusing on developing innovative products, such as immunotherapy, to improve treatment options and outcomes for patients. Immunotherapy involves harnessing the body's immune system to detect and combat cancer cells by boosting or activating immune responses. For instance, in March 2024, ImmunityBio Inc., a US-based biotechnology company, received approval from the Food and Drug Administration (FDA) for ANKTIVA (N-803) in the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) featuring carcinoma in situ (CIS), with or without papillary tumors. This approval is based on promising clinical trial results, which show that ANKTIVA, when used in combination with Bacillus Calmette-Guérin (BCG), offers a viable treatment option for patients who have not responded to standard BCG therapy. ANKTIVA is a pioneering IL-15 agonist immunotherapy that works by enhancing the immune system, specifically stimulating natural killer (NK) cells and CD8+ killer T cells to target and destroy cancer cells.

Need data on a specific region in this market?
Request Regional Data

What Is The Regional Outlook For The Global Non-Muscle Invasive Bladder Cancer Market?

North America was the largest region in the non-muscle invasive bladder cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Non-Muscle Invasive Bladder Cancer Market?

The non-muscle invasive bladder cancer market consists of revenues earned by entities by providing services such as diagnostic services, patient support services, and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-muscle invasive bladder cancer market also includes sales of molecular profiling kits and bladder instillation devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Non-Muscle Invasive Bladder Cancer Industry?

The non-muscle invasive bladder cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-muscle invasive bladder cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Non-Muscle Invasive Bladder Cancer Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $3.66 billion
Revenue Forecast In 2034 $4.58 billion
Growth Rate CAGR of 5.7% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The non-muscle invasive bladder cancer market covered in this report is segmented –
1) By Stage: Carcinoma In Situ (CIS), T1 Stage, Ta Stage
2) By Treatment: Immunotherapy, Chemotherapy, Surgery, Intravesical Therapy, Others Treatments
3) By Tumor: Low-Grade Tumours, High-Grade Tumours
4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments:
1) By Carcinoma In Situ (CIS): High-Grade CIS, Low-Grade CIS
2) By T1 Stage: T1a Stage (Superficial Tumors), T1b Stage (Invasive Into Lamina Propria)
3) By Ta Stage: Low-Grade Ta Stage, High-Grade Ta Stage
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Johnson & Johnson, Janssen Research & Development LLC, Merck & Co. Inc., AstraZeneca plc, Moderna Inc., Astellas Pharma US Inc., Ferring Pharmaceuticals, EMD Serono Inc., Fidia Farmaceutici SpA, Genentech Inc., Aura Biosciences Inc., UroGen Pharma Ltd., Asieris Pharmaceuticals, Protara Therapeutics Inc., Hamlet Pharma AB, Istari Oncology Inc., Heat Biologics Inc., Telormedix SA, Viventia Bio Inc., Theralase Technologies Inc., Vaxiion Therapeutics Inc., ImmunityBio Inc., Altor BioScience Corporation, SURGE Therapeutics Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Non-Muscle Invasive Bladder Cancer Market Characteristics

3. Non-Muscle Invasive Bladder Cancer Market Trends And Strategies

4. Non-Muscle Invasive Bladder Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Non-Muscle Invasive Bladder Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global Non-Muscle Invasive Bladder Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Non-Muscle Invasive Bladder Cancer Market Growth Rate Analysis

5.4. Global Non-Muscle Invasive Bladder Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Non-Muscle Invasive Bladder Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Non-Muscle Invasive Bladder Cancer Total Addressable Market (TAM)

6. Non-Muscle Invasive Bladder Cancer Market Segmentation

6.1. Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Carcinoma In Situ (CIS)

T1 Stage

Ta Stage

6.2. Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Immunotherapy

Chemotherapy

Surgery

Intravesical Therapy

Other Treatments

6.3. Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Low-Grade Tumours

High-Grade Tumours

6.4. Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

6.5. Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of Carcinoma In Situ (CIS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

High-Grade CIS

Low-Grade CIS

6.6. Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of T1 Stage, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

T1a Stage (Superficial Tumors)

T1b Stage (Invasive Into Lamina Propria)

6.7. Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of Ta Stage, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Low-Grade Ta Stage

High-Grade Ta Stage

7. Non-Muscle Invasive Bladder Cancer Market Regional And Country Analysis

7.1. Global Non-Muscle Invasive Bladder Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Non-Muscle Invasive Bladder Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market

8.1. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Muscle Invasive Bladder Cancer Market

9.1. China Non-Muscle Invasive Bladder Cancer Market Overview

9.2. China Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Muscle Invasive Bladder Cancer Market

10.1. India Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Muscle Invasive Bladder Cancer Market

11.1. Japan Non-Muscle Invasive Bladder Cancer Market Overview

11.2. Japan Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Muscle Invasive Bladder Cancer Market

12.1. Australia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Muscle Invasive Bladder Cancer Market

13.1. Indonesia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Muscle Invasive Bladder Cancer Market

14.1. South Korea Non-Muscle Invasive Bladder Cancer Market Overview

14.2. South Korea Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Muscle Invasive Bladder Cancer Market

15.1. Western Europe Non-Muscle Invasive Bladder Cancer Market Overview

15.2. Western Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Muscle Invasive Bladder Cancer Market

16.1. UK Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Muscle Invasive Bladder Cancer Market

17.1. Germany Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Muscle Invasive Bladder Cancer Market

18.1. France Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Muscle Invasive Bladder Cancer Market

19.1. Italy Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Muscle Invasive Bladder Cancer Market

20.1. Spain Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Muscle Invasive Bladder Cancer Market

21.1. Eastern Europe Non-Muscle Invasive Bladder Cancer Market Overview

21.2. Eastern Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Muscle Invasive Bladder Cancer Market

22.1. Russia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Muscle Invasive Bladder Cancer Market

23.1. North America Non-Muscle Invasive Bladder Cancer Market Overview

23.2. North America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Muscle Invasive Bladder Cancer Market

24.1. USA Non-Muscle Invasive Bladder Cancer Market Overview

24.2. USA Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Muscle Invasive Bladder Cancer Market

25.1. Canada Non-Muscle Invasive Bladder Cancer Market Overview

25.2. Canada Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Muscle Invasive Bladder Cancer Market

26.1. South America Non-Muscle Invasive Bladder Cancer Market Overview

26.2. South America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Muscle Invasive Bladder Cancer Market

27.1. Brazil Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Muscle Invasive Bladder Cancer Market

28.1. Middle East Non-Muscle Invasive Bladder Cancer Market Overview

28.2. Middle East Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Muscle Invasive Bladder Cancer Market

29.1. Africa Non-Muscle Invasive Bladder Cancer Market Overview

29.2. Africa Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Muscle Invasive Bladder Cancer Market Competitive Landscape And Company Profiles

30.1. Non-Muscle Invasive Bladder Cancer Market Competitive Landscape

30.2. Non-Muscle Invasive Bladder Cancer Market Company Profiles

30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Janssen Research & Development LLC Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Non-Muscle Invasive Bladder Cancer Market Other Major And Innovative Companies

31.1. Astellas Pharma US Inc.

31.2. Ferring Pharmaceuticals

31.3. EMD Serono Inc.

31.4. Fidia Farmaceutici SpA

31.5. Genentech Inc.

31.6. Aura Biosciences Inc.

31.7. UroGen Pharma Ltd.

31.8. Asieris Pharmaceuticals

31.9. Protara Therapeutics Inc.

31.10. Hamlet Pharma AB

31.11. Istari Oncology Inc.

31.12. Heat Biologics Inc.

31.13. Telormedix SA

31.14. Viventia Bio Inc.

31.15. Theralase Technologies Inc.

32. Global Non-Muscle Invasive Bladder Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Muscle Invasive Bladder Cancer Market

34. Recent Developments In The Non-Muscle Invasive Bladder Cancer Market

35. Non-Muscle Invasive Bladder Cancer Market High Potential Countries, Segments and Strategies

35.1 Non-Muscle Invasive Bladder Cancer Market In 2029 - Countries Offering Most New Opportunities

35.2 Non-Muscle Invasive Bladder Cancer Market In 2029 - Segments Offering Most New Opportunities

35.3 Non-Muscle Invasive Bladder Cancer Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of Carcinoma In Situ (CIS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of T1 Stage, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of Ta Stage, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Non-Muscle Invasive Bladder Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Non-Muscle Invasive Bladder Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Johnson & Johnson Financial Performance
  • Table 79: Janssen Research & Development LLC Financial Performance
  • Table 80: Merck & Co. Inc. Financial Performance
  • Table 81: AstraZeneca plc Financial Performance
  • Table 82: Moderna Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of Carcinoma In Situ (CIS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of T1 Stage, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of Ta Stage, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Non-Muscle Invasive Bladder Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Non-Muscle Invasive Bladder Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Johnson & Johnson Financial Performance
  • Figure 79: Janssen Research & Development LLC Financial Performance
  • Figure 80: Merck & Co. Inc. Financial Performance
  • Figure 81: AstraZeneca plc Financial Performance
  • Figure 82: Moderna Inc. Financial Performance

Emerging Trends and Growth Drivers in the Pediatric Dental Market Through 2029

Read More About Emerging Trends and Growth Drivers in the Pediatric Dental Market Through 2029

Competitive and Market Trend Analysis of Pharmaceutical Cold Chain Packaging Industry Through 2029

Read More About Competitive and Market Trend Analysis of Pharmaceutical Cold Chain Packaging Industry Through 2029

Key Market Drivers, Trends, and Forecast for the Global Pharmaceutical Warehousing Industry

Read More About Key Market Drivers, Trends, and Forecast for the Global Pharmaceutical Warehousing Industry

2025 Analysis: Opportunities and Risks in the Evolving Precision Genomic Testing Market

Read More About 2025 Analysis: Opportunities and Risks in the Evolving Precision Genomic Testing Market

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

Read More About A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Read More About A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Read More About Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Read More About Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Urinary Tract Cancer Global Market Report 2025 – By Cancer Type (Bladder Cancer, Urethral Cancer, Ureteric And Renal Pelvic Cancer), By Treatment (Chemotherapy, Intravesical Therapy, Radiation Therapy, Surgery), By Diagn...

View Report

Bladder Cancer Drugs Global Market Report 2025 – By Type (Non-Muscle-Invasive Bladder Cancer, Muscle-Invasive Bladder Cancer), By Application (Low-Grade Tumors, High-Grade Tumors), By Distribution Channel (Hospital Pharm...

View Report

Adrenocortical Carcinoma Global Market Report 2025 – By Type (Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma), By Therapy (Surgery, Laparoscopic Surgery, Open Surgery, Chemotherapy, Targeted Ther...

View Report

Urothelial Carcinoma Treatment Global Market Report 2025 – By Type (Non-Invasive Urothelial Carcinoma Treatment, Invasive Urothelial Carcinoma Treatment), By Treatment (Immunotherapy, Radiotherapy, Chemotherapy), By Canc...

View Report

Overactive Bladder Treatment Global Market Report 2025 – By Diseases Type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity), By Therapy (Anticholinergics, Mirabegron, Neurostimulation, Intravesical Insti...

View Report

Pediatric Bladder Treatment Global Market Report 2025 – By Type (Diurnal Incontinence, Enuresis, Other Types), By Treatment (Urotherapy, Medication, Surgical Reconstruction, Other Treatments), By Route of Administration ...

View Report

Urothelial Cancer Drugs Global Market Report 2025 – By Type( Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma), By Treatment( Immunotherapy, Chemotherapy, Preservation Therapy), By Distribution Channel( Hosp...

View Report

Basal Cell Carcinoma Treatment Global Market Report 2025 – By Treatment (Surgery, Medication, Other Treatments), By Route Of Administration (Oral, Parenteral, Other Route Of Administrations), By Distribution Channel (Hos...

View Report

Frequently Asked Questions

Non-muscle invasive bladder cancer (NMIBC) refers to a type of bladder cancer that is confined to the inner layers of the bladder wall and has not spread to the muscle layer. It is typically diagnosed at an early stage and can often be treated effectively with methods such as transurethral resection, intravesical therapy, or close surveillance. For further insights on this market, request a sample here

The market major growth driver - The Growing Demand for Minimally Invasive Procedures Driving The Market. For further insights on this market, request a sample here

The non-muscle invasive bladder cancer market size has grown strongly in recent years. It will grow from $3.46 billion in 2024 to $3.66 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to growth in the aging population, growth in healthcare spending, growth in healthcare infrastructure, growth in telemedicine, and a rise in smoking rates. The non-muscle invasive bladder cancer market size is expected to see strong growth in the next few years. It will grow to " $4.58 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to rising adoption of targeted therapies, increasing focus on personalized medicine, growing investments in oncology research, growing demand for minimally invasive procedures, and rising incidence of chronic bladder. Major trends in the forecast period include technological advancements, precision medicine, artificial intelligence, telemedicine, and digital health tools. For further insights on this market, request a sample here

The non-muscle invasive bladder cancermarket covered in this report is segmented –
1) By Stage: Carcinoma In Situ (CIS); T1 Stage; Ta Stage
2) By Treatment: Immunotherapy; Chemotherapy; Surgery; Intravesical Therapy; Others Treatments
3) By Tumor: Low-Grade Tumours; High-Grade Tumours
4) By End-User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy Subsegments:
1) By Carcinoma In Situ (CIS): High-Grade CIS; Low-Grade CIS
2) By T1 Stage: T1a Stage (Superficial Tumors); T1b Stage (Invasive Into Lamina Propria)
3) By Ta Stage: Low-Grade Ta Stage; High-Grade Ta Stage For further insights on this market, request a sample here

North America was the largest region in the non-muscle invasive bladder cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-muscle invasive bladder cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the non-muscle invasive bladder cancer market are Johnson & Johnson, Janssen Research & Development LLC, Merck & Co. Inc., AstraZeneca plc, Moderna Inc., Astellas Pharma US Inc., Ferring Pharmaceuticals, EMD Serono Inc., Fidia Farmaceutici SpA, Genentech Inc., Aura Biosciences Inc., UroGen Pharma Ltd., Asieris Pharmaceuticals, Protara Therapeutics Inc., Hamlet Pharma AB, Istari Oncology Inc., Heat Biologics Inc., Telormedix SA, Viventia Bio Inc., Theralase Technologies Inc., Vaxiion Therapeutics Inc., ImmunityBio Inc., Altor BioScience Corporation, SURGE Therapeutics Inc. . For further insights on this market, request a sample here.

Major trends in this market include Advancing Immunotherapy With FDA Approval Of ANKTIVA For BCG-Unresponsive Bladder Cancer. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Non Muscle Invasive Bladder Cancer Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon